Asian Tech Press (Dec 10) -- The U.S. Food and Drug Administration (FDA) approved on Thursday a booster dose of the COVID-19 vaccine co-developed by Pfizer Inc. and German company BioNTech SE for 16- to 17-year-olds.

The FDA amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine, approving a single booster dose for administration to people aged 16 to 17 years at least six months after receiving a second dose of the Pfizer-BioNTech vaccine.

Last month, the FDA had approved a booster dose of Pfizer and Moderna's COVID-19 vaccine boosters to all individuals 18 years of age and older